Introduction: Carpal tunnel syndrome (CTS) is compressive neuropathy of median nerve at the point where the nerve passes through the carpal tunnel, and it is the most common compressive neuropathy. Classic symptoms include pain, paresthesia, numbness, swelling, weakness and clumsiness of fingers (typically in the first three fingers). CTS can occur in one or both hands. Case presentation: We report a patient with carpal tunnel syndrome in the presence of Martin-Gruber anastomosis (median to ulnar anastomosis in the forearm) with atypical clinical presentation of CTS in terms of numbness of the first three fingers of the right hand and unexpected electromyoneurography examination (absurdly high speed motor velocity through the median nerve). Conclusion: The presence of anomalous communications between median and ulnar nerves (MGA anastomosis) is not so rare condition and we have to keep in mind this fact in routine clinical and neuropysiological examination to avoid some diagnostic mistakes.

Background: Fatigue is usually defined as a subjective lack of physical and/or mental energy necessary for doing everyday activities. Fatigue is a subjective condition, and there is not a valid definition of fatigue after a stroke at the moment. Aim: The analysis of frequency of fatigue syndrome in 200 patients after an ischemic stroke and its effect on cognitive functioning and quality of life after an ischemic stroke was conducted. The measuring instruments for the assessment of fatigue used were the Chalder Fatigue Scale, for cognitive functioning the Mini-Mental State Examination, and for the quality of life SF-36, scale for measuring quality of life. Neurological and neuropsychological testings of the participants were conducted three months after an ischemic stroke – first testing, six months after an ischemic stroke – second testing, and twelve months after an ischemic stroke – third testing. Results: Fatigue syndrome was noted in 68% of the patients three months after an ischemic stroke, in 71% in testing after six months, and 70% after twelve months. The mean values of MMSE score in the patients with and without fatigue syndrome was between 28 and 29 in all testings, which indicates that they had normal cognitive functioning. The significance of differences in the MMSE score in the patients with and without fatigue syndrome in the first, second and third testing was tested using HI-squared test and the results showed that there were no statistically significant differences (p>0.005). In comparison of quality of life between the patients with and without fatigue the results showed that the patients without fatigue syndrome had significantly better quality of life in comparison with the patients with fatigue syndrome in the field of mental and physical health (p< 0.0001). Conclusion: Fatigue syndrome after an ischemic stroke has a significant frequency (68-71%) and duration. Fatigue syndrome does not affect cognitive functioning of patients after an ischemic stroke but it leads to impaired quality of life of patients in all areas.

Erythroid enucleation is the process by which the future red blood cell disposes of its nucleus prior to entering the blood stream. This key event during red blood cell development has been likened to an asymmetric cell division (ACD), by which the enucleating erythroblast divides into two very different daughter cells of alternate molecular composition, a nucleated cell that will be removed by associated macrophages, and the reticulocyte that will mature to the definitive erythrocyte. Here we investigated gene expression of members of the Par, Scribble and Pins/Gpsm2 asymmetric cell division complexes in erythroid cells, and functionally tested their role in erythroid enucleation in vivo and ex vivo. Despite their roles in regulating ACD in other contexts, we found that these polarity regulators are not essential for erythroid enucleation, nor for erythroid development in vivo. Together our results put into question a role for cell polarity and asymmetric cell division in erythroid enucleation.

Abstract Background: This article summarizes the European Renal Association – European Dialysis and Transplant Association Registry’s 2014 annual report. It describes the epidemiology of renal replacement therapy (RRT) for end-stage renal disease (ESRD) in 2014 within 35 countries. Methods: In 2016, the ERA-EDTA Registry received data on patients who in 2014 where undergoing RRT for ESRD, from 51 national or regional renal registries. Thirty-two registries provided individual patient level data and 19 provided aggregated patient level data. The incidence, prevalence and survival probabilities of these patients were determined. Results: In 2014, 70 953 individuals commenced RRT for ESRD, equating to an overall unadjusted incidence rate of 133 per million population (pmp). The incidence ranged by 10-fold; from 23 pmp in the Ukraine to 237 pmp in Portugal. Of the patients commencing RRT, almost two-thirds were men, over half were aged ≥65 years and a quarter had diabetes mellitus as their primary renal diagnosis. By day 91 of commencing RRT, 81% of patients were receiving haemodialysis. On 31 December 2014, 490 743 individuals were receiving RRT for ESRD, equating to an unadjusted prevalence of 924 pmp. This ranged throughout Europe by more than 10-fold, from 157 pmp in the Ukraine to 1794 pmp in Portugal. In 2014, 19 406 kidney transplantations were performed, equating to an overall unadjusted transplant rate of 36 pmp. Again this varied considerably throughout Europe. For patients commencing RRT during 2005–09, the 5-year-adjusted patient survival probabilities on all RRT modalities was 63.3% (95% confidence interval 63.0–63.6). The expected remaining lifetime of a 20- to 24-year-old patient with ESRD receiving dialysis or living with a kidney transplant was 21.9 and 44.0 years, respectively. This was substantially lower than the 61.8 years of expected remaining lifetime of a 20-year-old patient without ESRD.

Raman spectroscopy is a noninvasive and label-free optical technique that provides detailed information about the molecular composition of a sample. In this study, we evaluated the potential of Raman spectroscopy to predict skin toxicity due to tyrosine kinase inhibitors treatment. We acquired Raman spectra of skin of patients undergoing treatment with MEK, EGFR, or BRAF inhibitors, which are known to induce severe skin toxicity; for this pilot study, three patients were included for each inhibitor. Our algorithm, based on partial least squares-discriminant analysis (PLS-DA) and cross-validation by bootstrapping, discriminated to variable degrees spectra from patient suffering and not suffering cutaneous adverse events. For MEK and EGFR inhibitors, discriminative power was more than 90% in the viable epidermis skin layer; whereas for BRAF inhibitors, discriminative power was 71%. There was a 81.5% correlation between blood drug concentration and Raman signature of skin in the case of EGFR inhibitors and viable epidermis skin layer. Our results demonstrate the power of Raman spectroscopy to detect apparition of skin toxicity in patients treated with tyrosine kinase inhibitors at levels not detectable via dermatological inspection and histological evaluation. Cancer Res; 77(2); 557-65. ©2016 AACR.